Gain Therapeutics Reports Promising Phase 1b Data for Parkinson’s Drug GT-02287
Event summary
- Gain Therapeutics reported stable MDS-UPDRS scores over 150 days of GT-02287 treatment in Phase 1b extension study.
- GT-02287 reduced glucosylsphingosine (GluSph) levels by 81% in participants with elevated baseline levels.
- Company presented preclinical data on GT-04686, a novel GCase allosteric modulator, at AD/PD™ 2026.
- Gain Therapeutics reported a net loss of $20.2 million for 2025, with cash reserves of $20.8 million.
- Phase 2 clinical trial for GT-02287 expected to begin in 3Q26, pending FDA IND clearance in 2Q26.
The big picture
Gain Therapeutics' Phase 1b data for GT-02287 supports its potential as a disease-modifying therapy for Parkinson’s disease, addressing a significant unmet need. The company’s focus on allosteric modulators and proprietary Magellan™ platform positions it in the competitive landscape of neurodegenerative disease treatments. With Phase 2 trials on the horizon and a novel preclinical asset in GT-04686, Gain Therapeutics is navigating the critical path from clinical validation to commercialization.
What we're watching
- Regulatory Timing
- Whether Gain Therapeutics can secure FDA IND clearance for GT-02287 by 2Q26 and initiate Phase 2 trials in 3Q26.
- Clinical Efficacy
- The durability of MDS-UPDRS score stability and biomarker reductions in the Phase 1b extension study results expected in 4Q26.
- Pipeline Progression
- The pace at which GT-04686 advances toward IND-enabling studies and potential expansion into other neurological disorders.
Related topics